携带HIV-1 E157Q整合酶多态性患者不同一线抗逆转录病毒治疗方案的病毒学结局:一项多中心回顾性研究
该多中心回顾性研究纳入2008至2019年启动ART前整合酶基因型耐药检测发现E157Q的初治HIV感染者,比较不同一线方案的病毒学结局。结果显示,含二代INSTI方案在病毒抑制率、达到病毒抑制时间和病毒反弹时间方面与PI方案相似或更优,支持将指南对多数HIV感染者的二代INSTI一线推荐同样适用于携带E157Q者。
要点
- 4043例初治HIV感染者中167例(4.1%)检出E157Q。
- 144例有ART后临床数据,中位随访1888天。
- INSTI-2组病毒抑制率、达抑制时间及反弹时间与PI组相似或更优。
核心结论
- 指南对多数HIV感染者推荐以二代INSTI为基础的一线ART,该推荐同样适用于携带E157Q的HIV感染者。
研究设计与样本
- 多中心回顾性观察性研究,纳入2008至2019年启动ART前接受整合酶基因型耐药检测并检出E157Q的初治HIV感染者。
- 4043例初治HIV感染者中167例(4.1%)检出E157Q,其中144例有ART启动后的临床数据,中位随访1888天。
主要发现
- 144例中,45例启动蛋白酶抑制剂+2种NRTI(PI组),33例启动一代INSTI(拉替拉韦或艾维雷韦/考比司他)+2种NRTI(INSTI-1组),58例启动每日一次二代INSTI(多替拉韦或比克替拉韦)+2种NRTI(INSTI-2组),8例启动其他方案。
- 多因素分析中,INSTI-2组在病毒抑制率、达到病毒抑制时间和病毒反弹时间方面与PI组相似或更优。
- INSTI-1组有2例发生病毒学失败。
关键数值与推荐
- 病毒抑制定义为<50拷贝/mL,病毒反弹定义为≥100拷贝/mL。
- E157Q在初治HIV感染者中检出率为4.1%(167/4043)。
临床怎么用
- 作者结论认为,指南对多数HIV感染者推荐以二代INSTI为基础的一线ART,该推荐同样适用于携带E157Q的HIV感染者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are recommended as first-line ART for people living with HIV (PLWH) in most guidelines. The INSTI-resistance-associated mutation E157Q, a highly prevalent (2%-5%) polymorphism of the HIV-1 (human immunodeficiency virus type 1) integrase gene, has limited data on optimal first-line ART regimens. We assessed the virological outcomes of various first-line ART regimens in PLWH with E157Q in real-world settings. METHODS: A multicentre retrospective observational study was conducted on PLWH who underwent integrase genotypic drug-resistance testing before ART initiation between 2008 and 2019 and were found to have E157Q. Viral suppression (<50 copies/mL) rate at 24 and 48 weeks, time to viral suppression and time to viral rebound (≥100 copies/mL) were compared among the first-line ART regimens. RESULTS: E157Q was detected in 167 (4.1%) of 4043 ART-naïve PLWH. Among them, 144 had available clinical data after ART initiation with a median follow-up of 1888 days. Forty-five started protease inhibitors + 2 NRTIs (PI group), 33 started first-generation INSTI (raltegravir or elvitegravir/cobicistat) + 2 NRTIs (INSTI-1 group), 58 started once-daily second-generation INSTI (dolutegravir or bictegravir) + 2 NRTIs (INSTI-2 group) and eight started other regimens. In the multivariate analysis, the INSTI-2 group showed similar or favourable outcomes compared with the PI group for viral suppression rates, time to viral suppression and time to viral rebound. Two cases in the INSTI-1 group experienced virological failure. CONCLUSIONS: The general guideline recommendation of second-generation INSTI-based first-line ART for most PLWH is also applicable to PLWH harbouring E157Q.
引用
- Uno S, Gatanaga H, Hayashida T, et al. Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study. J Antimicrob Chemother. 2023. PMID: 37856677. doi:10.1093/jac/dkad319
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。